Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

A year ago, Eli Lilly & Co. was poised to become the first pharmaceutical company to register a trillion-dollar market ...

Novo Nordisk is attractively valued after the sell-off, but near-term recovery requires patience. Read why I'm downgrading ...

The Washington Post says it has obtained documents that detail the five-year experiment involving state Medicaid programs and Medicare Part D plans. Plus: CMS has bumped up Medicare payments for ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

CVS Health raised its full-year profit forecast after exceeding Wall Street quarterly earnings estimates on Thursday, as ...

New Data Shows Continued Clinically Significant Outcomes, Including Improvements Across Blood Sugar, Medication Reduction and ...

We recently published 10 Stocks That Jim Cramer Talked About. CVS Health Corporation (NYSE:CVS) is one of the stocks Jim ...

Tack on a half-dozen zeros to your CVS receipt and you'll get a sense of the sticker shock afflicting state officials, insurers and hospitals dealing with the soaring cost of prescription drugs in ...

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

Novo Nordisk appointed longtime international operations head Maziar Mike Doustdar as CEO on Aug. 7, a surprise insider pick after slumping sales of its blockbuster weight‑loss ...

The appointment came shortly after Novo slashed its financial forecast, predicting this year’s sales will grow 8% to 14%, ...